Treatment of Hypercalcemia of Malignancy.

Marlene Chakhtoura, Ghada El-Hajj Fuleihan

Journal: Endocrinology and metabolism clinics of North America 2022;50(4):781-792

PMID: 34774248

Full Text on Elsevier Science View on PubMed

Abstract

The treatment of hypercalcemia of malignancy (HCM) consists of enhancing renal calcium excretion, mostly through hydration with isotonic fluids and the use of antiresorptive therapies. Intravenous zoledronic acid is currently the first-line treatment. Subcutaneous denosumab is used for bisphosphonate-refractory hypercalcemia and in patients with renal failure. There is no evidence that bisphosphonates prevent the occurrence of HCM. Conversely, denosumab, compared with zoledronic acid, is associated with a lower risk of HCM, both first episode and recurrence, in patients with breast cancer and multiple myeloma.

Address: Calcium Metabolism and Osteoporosis Program, Division of Endocrinology, WHO Collaborating Center for Metabolic Bone Disorders, American University of Beirut, PO Box 11-236, Riad El-Solh, Beirut 1107 2020, Lebanon.; Calcium Metabolism and Osteoporosis Program, Division of Endocrinology, WHO Collaborating Center for Metabolic Bone Disorders, American University of Beirut, PO Box 11-236, Riad El-Solh, Beirut 1107 2020, Lebanon. Electronic address: [email protected].

DOI: 10.1016/j.ecl.2021.08.002

Link outs

Free resources

Medical:

https://medlineplus.gov/cancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Bone Density Conservation Agents, Denosumab, Diphosphonates, Humans, Hypercalcemia, Neoplasms, Zoledronic Acid